Alkermes to Participate in Two Upcoming Investor Conferences

11/11/24 4:00:00 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ALKS alert in real time by email

DUBLIN, Nov. 11, 2024 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) announced today that management will participate at two upcoming investor conferences.

Stifel Healthcare Conference

Date/Time: Monday, Nov. 18, 2024 at 8:35 a.m. ET (1:35 p.m. GMT)

Jefferies London Healthcare Conference

Date/Time: Tuesday, Nov. 19, 2024 at 8:00 a.m. ET (1:00 p.m. GMT)

The live webcasts may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

About Alkermes plc

Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

Alkermes Contact:

Jamie Constantine

Investor Relations

+1 781 873 2402

View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-to-participate-in-two-upcoming-investor-conferences-302301608.html

SOURCE Alkermes plc

Get the next $ALKS alert in real time by email

Recent Analyst Ratings for

$ALKS

Date	Price Target	Rating	Analyst
11/5/2024	$25.00 → $36.00	Hold → Buy	Stifel
6/17/2024	$34.00	Buy	TD Cowen
3/19/2024	$37.00	Outperform	Robert W. Baird
2/20/2024	$25.00	Neutral → Sell	UBS
11/20/2023	$33.00	Neutral	JP Morgan
10/24/2023		In-line → Outperform	Evercore ISI
10/17/2023	$31.00	Neutral	UBS
11/3/2022	$26.00 → $30.00	Neutral → Overweight	Piper Sandler

More analyst ratings

Alkermes to Participate in Two Upcoming Investor Conferences

Chat with this insight

Recent Analyst Ratings for $ALKS

$ALKS Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

EVP R&D, Chief Medical Officer Hopkinson Craig C. exercised 43,058 units of Ordinary Shares at a strike of $20.03 and sold $1,774,576 worth of Ordinary Shares (58,996 units at $30.08), decreasing direct ownership by 16% to 83,300 units (SEC Form 4)

EVP R&D, Chief Medical Officer Hopkinson Craig C. sold $309,169 worth of Ordinary Shares (10,471 units at $29.53), decreasing direct ownership by 10% to 99,238 units (SEC Form 4)

EVP, CLO, Alkermes, Inc. Gaffin David Joseph converted options into 2,014 units of Ordinary Shares and covered exercise/tax liability with 895 units of Ordinary Shares, increasing direct ownership by 0.68% to 165,901 units (SEC Form 4)

$ALKS Press Releases

Fastest customizable press release news feed in the world

Alkermes to Participate in Two Upcoming Investor Conferences

Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall 2024 Scientific Conferences

Alkermes plc Reports Third Quarter 2024 Financial Results

$ALKS Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Alkermes Plc upgraded by Stifel with a new price target

TD Cowen initiated coverage on Alkermes Plc with a new price target

Robert W. Baird initiated coverage on Alkermes Plc with a new price target

$ALKS Financials

Live finance-specific insights

Alkermes plc Reports Third Quarter 2024 Financial Results

Alkermes to Report Third Quarter Financial Results on October 24, 2024

Alkermes plc Reports Second Quarter 2024 Financial Results

$ALKS Large Ownership Changes

This live feed shows all institutional transactions in real time.

$ALKS SEC Filings

$ALKS Market Insights

Live Market Insights

SEC Form SC 13G filed by Alkermes plc

Amendment: SEC Form SC 13G/A filed by Alkermes plc

Amendment: SEC Form SC 13G/A filed by Alkermes plc

SEC Form 10-Q filed by Alkermes plc

Alkermes plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Alkermes plc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

Cantor Fitzgerald Reiterates Overweight on Alkermes, Maintains $48 Price Target

JP Morgan Maintains Neutral on Alkermes, Raises Price Target to $32

Baird Maintains Outperform on Alkermes, Raises Price Target to $38

$ALKS Leadership Updates

Live Leadership Updates

Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors

Uber Technologies, Jabil and Builders FirstSource Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

Alkermes Appoints Caroline J. Loew, Ph.D., as Chief Executive Officer Designate of Mural Oncology plc

Recent Analyst Ratings for
$ALKS

$ALKS
Insider Trading

$ALKS
Press Releases

$ALKS
Analyst Ratings

$ALKS
Financials

$ALKS
Large Ownership Changes

$ALKS
SEC Filings

$ALKS
Market Insights

$ALKS
Leadership Updates